Literature DB >> 2421599

Diagnosis and immunotherapy of mould allergy. III. Diagnosis of Cladosporium allergy by means of symptom score, bronchial provocation test, skin prick test, RAST, CRIE and histamine release.

H J Malling, S Dreborg, B Weeke.   

Abstract

Thirty-three adult asthmatic patients suspected of mould allergy were investigated by in vivo and in vitro tests in order to establish a specific diagnosis of asthma caused by the mould species Cladosporium. The patients were evaluated by daily symptom scores in the peak Cladosporium season, bronchial provocation test (BPT), skin prick test (SPT), RAST, histamine release from basophil granulocytes (HIST), and crossed radioimmunoelectrophoresis (CRIE), and the results were scored as negative (score 0), equivocal (score 1) or positive (score 2). Based on daily symptom scores and the result of BPT the patients were classified as being manifest allergic (asthma) to Cladosporium (positive allergy), inconclusive or negative. Positive allergy was defined as asthma symptoms oscillating with the spore concentration and a BPT score 2 (positive at allergen concentration less than 10,000 BU). Negative allergy was defined as no asthma symptoms and a negative BPT (score 0) and inconclusive in the case of symptoms and BPT sum of score 1-3. According to the classification a final diagnosis (positive or negative) could be established in 85% of the patients. "False positive" tests were found: for BPT in 27%, SPT 18%, RAST 0%, HIST 18%, and CRIE 0%. The corresponding figures for "false negative" were: BPT 0%, SPT 0%, RAST 27%, HIST 18%, and CRIE 23%. The relative risk of being allergic in spite of a negative test result was 0% for BPT and SPT, and 25-30% with RAST, HIST, and CRIE. In the case of positive test the risk was 90-100%. Excluding BPT, SPT was found to be the optimal single test to predict/rule out clinical allergy. A stepwise combination of positive SPT and positive RAST was found exclusively in patients clinically evaluated as positive, and does not call for an additional BPT. Using a potent allergenic extract a negative SPT excluded clinically important allergy. The primary conclusion of the study, however, is that the final diagnosis of Cladosporium asthma could not be based on a positive BPT alone (due to "false positive"), but only on a combination of clinical symptoms during the spore season and a positive BPT.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421599     DOI: 10.1111/j.1398-9995.1986.tb00276.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Immunotherapy for mold allergy.

Authors:  H J Malling
Journal:  Clin Rev Allergy       Date:  1992

Review 2.  Diagnosis of mold allergy.

Authors:  H J Malling
Journal:  Clin Rev Allergy       Date:  1992

Review 3.  Mold allergens in respiratory allergy: from structure to therapy.

Authors:  Teresa E Twaroch; Mirela Curin; Rudolf Valenta; Ines Swoboda
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-11       Impact factor: 5.764

Review 4.  Fungal allergens.

Authors:  W E Horner; A Helbling; J E Salvaggio; S B Lehrer
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure: S2K Guideline of the German Society of Hygiene, Environmental Medicine and Preventive Medicine (GHUP) in collaboration with the German Association of Allergists (AeDA), the German Society of Dermatology (DDG), the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Occupational and Environmental Medicine (DGAUM), the German Society for Hospital Hygiene (DGKH), the German Society for Pneumology and Respiratory Medicine (DGP), the German Mycological Society (DMykG), the Society for Pediatric Allergology and Environmental Medicine (GPA), the German Federal Association of Pediatric Pneumology (BAPP), and the Austrian Society for Medical Mycology (ÖGMM).

Authors:  Gerhard A Wiesmüller; Birger Heinzow; Ute Aurbach; Karl-Christian Bergmann; Albrecht Bufe; Walter Buzina; Oliver A Cornely; Steffen Engelhart; Guido Fischer; Thomas Gabrio; Werner Heinz; Caroline E W Herr; Jörg Kleine-Tebbe; Ludger Klimek; Martin Köberle; Herbert Lichtnecker; Thomas Lob-Corzilius; Rolf Merget; Norbert Mülleneisen; Dennis Nowak; Uta Rabe; Monika Raulf; Hans Peter Seidl; Jens-Oliver Steiß; Regine Szewszyk; Peter Thomas; Kerttu Valtanen; Julia Hurraß
Journal:  Allergo J Int       Date:  2017-02-28

Review 6.  Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.

Authors:  Felix Asamoah; Artemisia Kakourou; Sangeeta Dhami; Susanne Lau; Ioana Agache; Antonella Muraro; Graham Roberts; Cezmi Akdis; Matteo Bonini; Ozlem Cavkaytar; Breda Flood; Kenji Izuhara; Marek Jutel; Ömer Kalayci; Oliver Pfaar; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2017-08-02       Impact factor: 5.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.